By Fineline Cube Eli Lilly and Company (NYSE: LLY) announced positive interim results from the Phase 1b Heart-2 study of VERVE-102, an investigational in vivo base editing medicine designed to durably turn off the PCSK9 gene in the liver and lower low-density lipoprotein cholesterol (LDL-C) following a single infusion.
Clinical Trial Highlights – Phase 1b Heart-2 Study
| Key Metric | Results |
|---|---|
| Study Population | 35 adults with heterozygous familial hypercholesterolemia (HeFH) or premature coronary artery disease (CAD) |
| Treatment | Single intravenous infusion of VERVE-102 at doses ranging from 0.3–1.0 mg/kg |
| Primary Outcomes | Dose-dependent reductions in PCSK9 protein and LDL-C across all dose levels |
| Durability | Sustained effects observed for up to 18 months post-treatment |
| Safety | Well tolerated across all dose levels with no significant safety concerns |
| Next Steps | Phase 2 clinical study initiation planned by end of 2026 |
Dose-Response Relationship – Interim Analysis
| Dose Level (mg/kg) | Mean PCSK9 Reduction | Mean LDL-C Reduction |
|---|---|---|
| 0.3 | 51% | 9% |
| 0.45 | Not specified | 44% |
| 0.6 | Not specified | 45% |
| 0.7 | Not specified | 33% |
| 0.8 | Not specified | 51% |
| 1.0 | 88% | 62% |
The data demonstrate a clear dose-dependent relationship with the highest dose (1.0 mg/kg) achieving 88% reduction in PCSK9 and 62% reduction in LDL-C, sustained for up to 18 months following a single administration.
Technology Platform & Innovation Profile
- Therapeutic Approach: In vivo base editing medicine – first-of-its-kind genomic medicine administered directly to patients
- Mechanism: Permanent silencing of PCSK9 gene in hepatocytes through precise DNA base editing
- Delivery System: Lipid nanoparticle (LNP) formulation enabling targeted liver delivery
- Differentiation: Single-dose, potentially curative approach versus chronic monoclonal antibody or siRNA therapies requiring regular administration
- Development Partnership: Originally developed by Verve Therapeutics; Lilly acquired exclusive worldwide rights in 2023
Market Impact & Competitive Landscape
- Addressable Population: Approximately 1.5 million patients in the US with HeFH plus millions more with premature CAD and elevated LDL-C
- Current Standard of Care: PCSK9 inhibitors (monoclonal antibodies: Repatha, Praluent) require bi-weekly injections; siRNA therapy (Leqvio) requires quarterly dosing
- Competitive Advantage: Single-dose durability could revolutionize treatment paradigm and significantly reduce lifetime treatment costs
- Pricing Implications: Potential for premium pricing ($1-2M per dose) justified by curative potential and elimination of chronic therapy costs
- Regulatory Pathway: Breakthrough Therapy Designation likely; accelerated approval possible based on LDL-C reduction as surrogate endpoint
Strategic Outlook & Development Timeline
- Phase 2 Initiation: Planned by end of 2026 with larger patient cohorts and longer follow-up
- Commercial Preparation: Manufacturing scale-up and regulatory strategy development underway
- Market Entry: Potential launch in 2029-2030 if Phase 2/3 trials confirm safety and efficacy
- Portfolio Integration: Complements Lilly’s existing cardiovascular portfolio and positions the company as a leader in genomic medicine
Forward-Looking Statements
This brief contains forward-looking statements regarding clinical trial results, regulatory approvals, development timelines, and commercial expectations for VERVE-102. Actual results may differ due to risks including clinical trial outcomes, regulatory decisions, safety findings, and competitive dynamics.-Fineline Info & Tech